We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Venn Life Sciences Holdings Plc | LSE:VENN | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.85 | 6.70 | 7.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
TIDMVENN
RNS Number : 9453T
Venn Life Sciences Holdings PLC
26 March 2019
26 March 2019
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Change of Adviser
Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces the appointment of Arden Partners plc as the Company's Nominated Adviser and Joint Broker with immediate effect, alongside its existing Joint Broker and ESM Adviser, Davy.
Enquiries:
Venn Life Sciences Holdings Plc Tel: +353 1 5499 341
Tony Richardson, Chief Executive Officer
Arden Partners (Nominated Advisor and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (ESM Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Fergal Meegan / Matthew de Vere White (Corporate Finance)
About Venn Life Sciences
Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.
Further information in relation to Venn Life Sciences www.vennlifesciences.com
Venn life Science: getintouch@vennlife.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
APPDELFLKXFLBBQ
(END) Dow Jones Newswires
March 26, 2019 03:01 ET (07:01 GMT)
1 Year Venn Life Sciences Chart |
1 Month Venn Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
